The 0.1 mg (100 mcg) dose used in the Empower ODT formulation was not determined through dose-finding studies specific to semaglutide users
The post-marketing surveillance requirements for retatrutide will likely be extensive, reflecting both the novelty of the triple agonist mechanism and the FDA's increased focus on long-term safety monitoring for obesity medications
To learn more about us or to schedule a consultation, call us today at (470) 785-4616 or fill out our online appointment request form
Esposito, K
Mechanisms of L-cell GLP-1 secretion Physiologically, L-cells, which are most common in the distal parts of the intestines [15], are stimulated to secrete all their secretory products (GLP-1, GLP-2, gut-derived glucagon [also called glicentin], peptide tyrosine tyrosine, oxyntomodulin) in response to nutrient ingestion [16, 17]
Obesity: once-daily oral GLP-1 orforglipron shows clinically meaningful weight loss - Vera Health NewsAskConsultDiscoverCalculateSign upSign upLoginLoginDiscover